• Explore /
  • Poster
  • / The survival outcomes for men with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination deficiencies (HRD) treated with radium-223: Princess Margaret Cancer Centre (PMCC) experience.

The survival outcomes for men with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination deficiencies (HRD) treated with radium-223: Princess Margaret Cancer Centre (PMCC) experience.

Abstract Poster

Authors

Esmail Al-Ezzi

Esmail M. Al-Ezzi

Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada

Esmail M. Al-Ezzi , Osama Abdeljalil , Katherine Lajkosz , Shreya S. Gramolini , Nely Mercy Diaz Mejia , Husam Alqaisi , Jenny Peng , Richard Thomas O'Dwyer , Mohammed Alghamdi , Sulaiman Almuthri , Vikaash Kumar , Di Maria Jiang , Nazanin Fallah-Rad , Srikala S. Sridhar

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Translational Research, Tumor Biology, Biomarkers, and Pathology

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr 179)

DOI

10.1200/JCO.2024.42.4_suppl.179

Abstract #

179

Poster Bd #

H8

Abstract Disclosures

Similar Posters

First Author: Mehmet Asim Bilen

First Author: Ruben Raychaudhuri

First Author: Nicholas D. James

First Author: Benedito A. Carneiro